Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV

NCT06691243 · Recruiting

Last updated 2026-05-28

This clinical trial is testing the safety of the medication semaglutide in adults with cocaine use disorder, both with and without HIV.

Status Recruiting Currently enrolling participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 40 people Planned (estimated).

Who can join Ages 18–65 · all sexes

Timeline Started 2025-08 · est. completion 2027-03

Where 2 sites · United States

What this study is testing ClinicalTrials.gov NCT06691243 ↗

Description as written by the study sponsor.

The purpose of this research study is to find out if semaglutide is safe and well tolerated in adults with cocaine use disorder who do and do not have human immunodeficiency virus (HIV). Participants will complete a screening process and if you are able to participate, you will be assigned to one of two treatment groups: semaglutide or placebo. Participants will: * Visit the clinic once a week for semaglutide or placebo injections * Visit the clinic once every two weeks for labwork, assessments and/or surveys * If consented to optional MRI's, complete two MRI's

Treatments tested

Semaglutide also known as Wegovy, Ozempic Drug

The initial dose will be semaglutide 0.25mg which, if tolerated, will be escalated to 0.5mg. Escalation will continue to 1.0 mg and afterwards to 2.0 mg. The highest possible dose will be 2.0mg semaglutide.
Placebo Drug

Patients randomized to placebo arm will receive placebo injection every week.

Main thing measured	Safety of semaglutide in patients with cocaine use disorder (CUD) with and without HIV
Sponsor	University of Maryland, Baltimore
Conditions studied	Cocaine Use Disorder, HIV
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06691243 ↗